Skip to Content

Join the 'Cuvitru' group to help and get support from people like you.

Cuvitru News

Shire Announces FDA Approval of Cuvitru [immune globulin subcutaneous (human)] for Primary Immunodeficiency

Posted 16 Sep 2016 by Drugs.com

Lexington, Mass. – September 14, 2016 – Shire plc (LSE: SHP, NASDAQ: SHPG) announced that the United States Food and Drug Administration (FDA) has granted approval for Cuvitru [Immune Globulin Subcutaneous (Human), 20% Solution] in adult and pediatric patients two years of age and older. Cuvitru is a treatment for patients with primary immunodeficiency (PI), a group of more than 300 genetic disorders in which part of the body’s immune system is missing or functions improperly; it affects up to six million people worldwide. With the approval of Cuvitru, Shire now has the broadest portfolio of intravenous and subcutaneous immunoglobulin (IG) products, including the only once-a-month subcutaneous treatment option. Cuvitru is the only 20% subcutaneous IG treatment option without proline and with the ability to infuse up to 60 mL (12 grams) per site and 60 mL per hour, per site as tolerat ... Read more

Related support groups: Primary Immunodeficiency Syndrome, Immunodeficiency, Immune Globulin Subcutaneous, Cuvitru

Ask a Question

Further Information

Related Condition Support Groups

Primary Immunodeficiency Syndrome

Cuvitru Patient Information at Drugs.com